Pfizer Inc. (NYSE:PFE) Shares Sold by Legacy Capital Group California Inc.
Legacy Capital Group California Inc. lessened its position in shares of Pfizer Inc. (NYSE:PFE – Free Report) by 5.4% in the 3rd quarter, according to its most recent filing with the Securities & ...
International Assets Investment Management LLC Takes $146.48 Million Position in Pfizer Inc. (NYSE:PFE)
International Assets Investment Management LLC purchased a new stake in Pfizer Inc. (NYSE:PFE – Free Report) during the third quarter, according to its most recent 13F filing with the SEC. The firm ...
Zacks.com on MSN1d
Pharma Stock Roundup: RHHBY Earnings, Drug Pipeline & Regulatory News
This week, Roche RHHBY announced its third-quarter and nine-month results. Sanofi SNY confirmed that it is holding exclusive ...
BioPharma Dive1d
Sanofi earnings boosted by Beyfortus, earlier vaccine sales
Sanofi and partner AstraZeneca recently increased production capacity for their RSV antibody shot, sales of which jumped ...
BioSpace1d
CDC Reaffirm RSV Vaccination Guidelines, Declines Expanding Coverage to Younger Adults
The CDC’s vaccine advisors on Thursday maintained that respiratory syncytial virus immunization is only recommended for ...
Just After Pfizer's RSV Vaccine Approval For Younger Adults, GSK Layouts Encouraging Preliminary Data Showing Potential For Use In Larger Population
GSK unveils new Arexvy data showing strong protection in adults 18-49 at risk for RSV. The vaccine could broaden coverage for ...
FiercePharma2d
GSK answers Pfizer's RSV approval with data targeting matching nod in younger adults
“These promising data add to the evidence supporting GSK’s RSV vaccine and could help expand protection to more adults at ...
pulmonologyadvisor2d
RSV Vaccine Abrysvo Approved for Adults Aged 18 to 59 at Increased Risk
FDA has approved Abrysvo for active immunization for the prevention of lower respiratory tract disease caused by RSV.
Pharmabiz2d
Pfizer receives US FDA approval for its RSV vaccine Abrysvo for adults aged 18 to 59 at increased risk for disease
Pfizer Inc. announced that the US Food and Drug Administration (FDA) has approved Abrysvo (Respiratory Syncytial Virus Vaccine), the company’s bivalent RSV prefusion F (RSVpreF) vaccine, for the ...
biopharma-reporter2d
The FDA has approved Pfizer’s RSV vaccine Abrysvo for adults aged 18 to 59
The US pharma giant Pfizer recently announced that its respiratory syncytial virus (RSV) vaccine Abrysvo has received FDA ...
McKnight's Long-Term Care News2d
FDA OKs Pfizer’s RSV vaccine for some adults under 60
On Tuesday, the US Food and Drug Administration approved Pfizer’s respiratory syncytial virus (RSV) vaccine, Abrysvo, for ...
PharmTech3d
FDA Approves RSV Vaccine
Pfizer’s bivalent RSV prefusion F vaccine has been approved to prevent lower respiratory tract disease resulting from the respiratory syncytial virus in adults 18 to 59 years of age who are at ...